Becton, Dickinson and Company (NYSE:BDX) Receives $275.63 Average PT from Analysts

Shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) have received a consensus recommendation of “Hold” from the ten analysts that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $275.63.

Several research analysts recently issued reports on the stock. Morgan Stanley increased their price target on shares of Becton, Dickinson and from $293.00 to $295.00 and gave the stock an “overweight” rating in a report on Monday, April 11th. Argus increased their price target on shares of Becton, Dickinson and from $275.00 to $310.00 in a report on Monday, February 28th. StockNews.com raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Saturday. Piper Sandler cut their price target on shares of Becton, Dickinson and from $265.00 to $255.00 in a report on Thursday, May 5th. Finally, SVB Leerink increased their price target on shares of Becton, Dickinson and from $270.00 to $275.00 and gave the stock a “market perform” rating in a report on Friday, February 4th.

Shares of NYSE:BDX traded down $1.28 on Monday, reaching $248.44. The company’s stock had a trading volume of 1,192,134 shares, compared to its average volume of 1,248,481. The stock’s 50-day moving average is $261.03 and its two-hundred day moving average is $257.26. Becton, Dickinson and has a 52-week low of $235.13 and a 52-week high of $280.62. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.52 and a quick ratio of 1.04. The stock has a market capitalization of $70.82 billion, a P/E ratio of 39.19, a PEG ratio of 3.51 and a beta of 0.64.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.20. Becton, Dickinson and had a net margin of 9.59% and a return on equity of 14.91%. The business had revenue of $5.01 billion during the quarter, compared to analysts’ expectations of $4.78 billion. During the same period in the prior year, the company earned $3.19 earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. Equities analysts forecast that Becton, Dickinson and will post 11.19 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 30th. Stockholders of record on Thursday, June 9th will be given a $0.87 dividend. This represents a $3.48 annualized dividend and a dividend yield of 1.40%. Becton, Dickinson and’s dividend payout ratio is presently 54.89%.

In other news, EVP Betty D. Larson sold 14,374 shares of the stock in a transaction that occurred on Friday, February 25th. The shares were sold at an average price of $271.90, for a total value of $3,908,290.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP David Hickey sold 475 shares of the firm’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $256.00, for a total transaction of $121,600.00. Following the sale, the executive vice president now owns 3,806 shares in the company, valued at approximately $974,336. The disclosure for this sale can be found here. 0.50% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in Becton, Dickinson and by 56.0% during the first quarter. Renaissance Technologies LLC now owns 181,272 shares of the medical instruments supplier’s stock worth $48,218,000 after acquiring an additional 65,100 shares during the last quarter. Jaffetilchin Investment Partners LLC raised its stake in Becton, Dickinson and by 38.1% during the first quarter. Jaffetilchin Investment Partners LLC now owns 1,548 shares of the medical instruments supplier’s stock worth $387,000 after purchasing an additional 427 shares during the period. ING Groep NV raised its stake in Becton, Dickinson and by 20.5% during the first quarter. ING Groep NV now owns 45,180 shares of the medical instruments supplier’s stock worth $12,018,000 after purchasing an additional 7,697 shares during the period. KCM Investment Advisors LLC raised its stake in Becton, Dickinson and by 7.5% during the first quarter. KCM Investment Advisors LLC now owns 6,528 shares of the medical instruments supplier’s stock worth $1,736,000 after purchasing an additional 455 shares during the period. Finally, Edgestream Partners L.P. purchased a new position in Becton, Dickinson and during the first quarter worth approximately $284,000. Hedge funds and other institutional investors own 86.58% of the company’s stock.

Becton, Dickinson and Company Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.